

## Growth Hormone: Children Less than 21 Years of Age

## **Member Information**

1.	Last Name:	2. First Name:5. Gender:					
3.	Trillium ID #:		4. Date of Birt	:h:	5. Gen	der:	
Pres	criber Information						
1.	Prescriber Name:	rescriber Name: 2. NPL #:					
3.	Requestor Name (Nur	rse/Office Staff):					
4.	Mailing Address:			City:	State:	Zip:	
5.	Phone #:		Ext	Fax #:			
Drug	g Information						
1.	Drug Name:	2. Stre	ngth:		_ 3. Quantity per 30 Days:		
					□ 120 Days □ 180 Days		
	ical Information	- /- /	,,-				
T. FO	Diagnosis: OR NON-PREFERRED DRUGS: COMPLETE THIS SECTION AS WELL						
	□ Failed two preferred drug(s). List preferred drugs failed:						
	OR list reason why	member cannot try two pi	referred drugs:				
3.	History of:  Turners Syndrome  Prader Willi Syndrome  Craniopharyngioma in the last 2 years Panhypopituitarism in the last 2 years  Cranial Irradiation in the last 2 years						
	🗆 MRI His	tory of Hypopituitarism	list:	🗆	Hypopituitarism		
			the last 2 years	s 🗆 SGA with	IUGR 🗆 Other:		
4.	Please check all that apply:						
	<ul> <li>Member has a height velocity &lt; 25th Percentile for Bone Age. Height Velocity:</li> <li>Member has low serum levels of IGF-1 and IGFBP-3 IGF-1 Level:</li> <li>IGFBP-3 Level:</li> </ul>						
				/el:	_ IGFBP-3 Level:	_	
	-	ons of hypopituitarism List					
		ately nourished child with I					
		3rd percentile for chronol			estational age with no catch up		
	□ Stim testing? Agent 1	:	Agent 2:		Peak:	Na/ml	
5.		member > 9 years old)?				g,	
6.				nt > 2.25 stand	ard deviations below mean fo	r age, and bone	
	age >2 standard deviations below mean, and low serum levels of IGF-1 and IGFBP-3?  Yes  No						
_		IGFBP-3 Level:		_			
7.		being treated? □ <b>Yes</b> □				-	
0		within age appropriate ra			entered puberty?  Yes  N	0	
	bitive only:	within age appropriate ra		NO Results.			
9.		rt bowel syndrome in the l	ast 2 vears? 🗆 `	Yes □ No			
Inc	relex only:	, <b>,</b>	<b>,</b>				
10.	Check all that apply:						
	🗆 History of GH product in last year 🛛 GH resistance is caused by mutation in GH receptor of post GH receptor signaling						
pathway 🛛 Patient has IGF-1 gene defects 🖾 GH gene deletions and patient has developed neutralizing antib					ntibodies to GH		
	$\Box$ Patient ht < 3 SD < m	ean and IGF-1 level < 3 S	D < Mean and n	ormal or eleva	ted GH levels.		
Si	gnature of Prescriber: _				Date:		
			gnature Mand	atory)			

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.